Abstract
Hyper- and dyslipidemia contribute to cardiovascular morbidity and mortality in diabetic patients. Pharmacological therapy to lower LDL cholesterol has convincingly shown to reduce cardiovascular risk in diabetic patients. The present article represents the recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in diabetic patients according to current scientific evidence.
Keywords:
Diabetes mellitus; Hyperlipidemia; Statins.
MeSH terms
-
Austria
-
Diabetes Complications / complications
-
Diabetes Complications / drug therapy*
-
Diabetic Cardiomyopathies / drug therapy*
-
Diabetic Cardiomyopathies / etiology
-
Diabetic Cardiomyopathies / prevention & control
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Evidence-Based Medicine
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hyperlipidemias / drug therapy*
-
Hyperlipidemias / etiology
-
Hyperlipidemias / prevention & control*
-
Hypolipidemic Agents / administration & dosage*
-
Practice Guidelines as Topic*
-
Treatment Outcome
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents